Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:ESPR
- CUSIP: N/A
- Web: www.esperion.com
Capitalization:- Market Cap: $1.06 billion
- Outstanding Shares: 22,590,000
Average Prices:- 50 Day Moving Avg: $43.30
- 200 Day Moving Avg: $32.54
- 52 Week Range: $9.40 - $50.52
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -9.82
- P/E Growth: -0.78
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $8.52 per share
- Price / Book: 5.50
Profitability:- EBIDTA: ($101,960,000.00)
- Return on Equity: -42.81%
- Return on Assets: -40.33%
Debt:- Current Ratio: 8.70%
- Quick Ratio: 8.70%
Misc:- Average Volume: 659,708 shs.
- Beta: 2.72
- Short Ratio: 7.13
Frequently Asked Questions for Esperion Therapeutics (NASDAQ:ESPR)
What is Esperion Therapeutics' stock symbol?
Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."
How were Esperion Therapeutics' earnings last quarter?
Esperion Therapeutics, Inc. (NASDAQ:ESPR) posted its quarterly earnings data on Monday, May, 1st. The company reported ($1.80) EPS for the quarter, missing the Zacks' consensus estimate of ($1.44) by $0.36. During the same quarter in the previous year, the company posted ($0.65) EPS. View Esperion Therapeutics' Earnings History.
Where is Esperion Therapeutics' stock going? Where will Esperion Therapeutics' stock price be in 2017?
11 equities research analysts have issued 12-month price objectives for Esperion Therapeutics' stock. Their predictions range from $12.50 to $60.00. On average, they anticipate Esperion Therapeutics' share price to reach $40.95 in the next year. View Analyst Ratings for Esperion Therapeutics.
What are analysts saying about Esperion Therapeutics stock?
Here are some recent quotes from research analysts about Esperion Therapeutics stock:
- 1. According to Zacks Investment Research, "Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. " (5/9/2017)
- 2. Needham & Company LLC analysts commented, "The FDA has agreed that the Phase III CLEAR LDL program of bempedoic acid is sufficient to support approval. This resolves a long standing issue for ESPR shares regarding the ability to get their drug approved without a completed CVOT. This regulatory confirmation comes on the heals of the positive FOURIER outcomes data for Repatha and the genetic validation of the target for bempedoic acid which was presented yesterday at the American College for Cardiology (ACC). As a result of this trifecta of positive news we are increasing our price target on ESPR to $58 from $25. We once again model US approval based on CLEAR LDL in 2020." (3/20/2017)
Who are some of Esperion Therapeutics' key competitors?
Some companies that are related to Esperion Therapeutics include Blueprint Medicines Corporation (BPMC), Emergent Biosolutions (EBS), Foundation Medicine (FMI), Global Blood Therapeutics (GBT), Momenta Pharmaceuticals (MNTA), Medpace Holdings (MEDP), Genomic Health (GHDX), Genus plc (GNS), Immunomedics (IMMU), Albany Molecular Research (AMRI), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Cellectis S.A. (CLLS), Arena Pharmaceuticals (ARNA), Enanta Pharmaceuticals (ENTA), TG Therapeutics (TGTX), Crispr Theraptc (CRSP), Editas Medicine (EDIT) and Intellia Therapeutics (NTLA).
Who are Esperion Therapeutics' key executives?
Esperion Therapeutics' management team includes the folowing people:
- Timothy M. Mayleben, President, Chief Executive Officer, Director
- Narendra D. Lalwani Ph.D., FAHA, DABT, Chief Operating Officer, Executive Vice President - Research & Development
- Mary P. McGowan M.D., Chief Medical Officer
- Nicole Vitullo MBA, Independent Lead Director
- Roger S. Newton Ph.D., FAHA, FACN, Director
- Scott N. Braunstein M.D., Independent Director
- Dov A. Goldstein M.D., Independent Director
- Antonio M. Gotto Jr., M.D., Ph.D., Independent Director
Who owns Esperion Therapeutics stock?
Esperion Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Meditor Group Ltd (2.51%), Peregrine Capital Management LLC (1.41%), Russell Investments Group Ltd. (0.10%), US Bancorp DE (0.04%), Aperio Group LLC (0.02%) and Creative Planning (0.01%). Company insiders that own Esperion Therapeutics stock include Dov A Md Goldstein, Gilbert S Omenn, Mark E Mcgovern, Narendra D Lalwani and Timothy M Mayleben. View Institutional Ownership Trends for Esperion Therapeutics.
Who sold Esperion Therapeutics stock? Who is selling Esperion Therapeutics stock?
Who bought Esperion Therapeutics stock? Who is buying Esperion Therapeutics stock?
Esperion Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Meditor Group Ltd, Peregrine Capital Management LLC, Aperio Group LLC and US Bancorp DE. Company insiders that have bought Esperion Therapeutics stock in the last two years include Gilbert S Omenn, Mark E Mcgovern, Narendra D Lalwani and Timothy M Mayleben. View Insider Buying and Selling for Esperion Therapeutics.
How do I buy Esperion Therapeutics stock?
Shares of Esperion Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Esperion Therapeutics' stock price today?
One share of Esperion Therapeutics stock can currently be purchased for approximately $46.86.
MarketBeat Community Rating for Esperion Therapeutics (NASDAQ ESPR)MarketBeat's community ratings are surveys of what our community members think about Esperion Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Esperion Therapeutics (NASDAQ:ESPR) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 6 Hold Ratings, 4 Buy Ratings, 1 Strong Buy Rating |
| Consensus Rating: | Buy (Score: 2.55) |
| Consensus Price Target: | $40.95 (12.61% downside) |
Analysts' Ratings History for Esperion Therapeutics (NASDAQ:ESPR)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/10/2017 | Jefferies Group LLC | Initiated Coverage | Hold -> Hold | $55.00 | Low |  |
| 6/26/2017 | Stifel Nicolaus | Reiterated Rating | Buy -> Buy | $45.00 -> $60.00 | Low | |
| 6/23/2017 | Deutsche Bank AG | Initiated Coverage | Buy | $48.00 | High | |
| 6/22/2017 | Citigroup Inc. | Reiterated Rating | Buy | | High | |
| 3/20/2017 | J P Morgan Chase & Co | Reiterated Rating | Hold | $22.00 -> $50.00 | Medium | |
| 3/20/2017 | Royal Bank Of Canada | Reiterated Rating | Hold | $45.00 | High | |
| 3/20/2017 | Needham & Company LLC | Boost Price Target | Strong-Buy -> Strong-Buy | $25.00 -> $58.00 | High | |
| 3/20/2017 | Credit Suisse Group | Upgrade | Underperform -> Neutral | $29.00 | High | |
| 11/6/2016 | JMP Securities | Reiterated Rating | Buy | | N/A | |
| 10/15/2016 | Chardan Capital | Reiterated Rating | Neutral | $12.50 | N/A | |
| 8/31/2016 | Barclays PLC | Set Price Target | Hold | $13.00 | N/A | |
| 7/5/2016 | WallachBeth Capital | Downgrade | Buy -> Hold | $35.00 | N/A | |
| 6/29/2016 | Lake Street Capital | Lower Price Target | Buy | $80.00 -> $27.00 | N/A | |
| 11/6/2015 | Bank of America Corporation | Reiterated Rating | Buy | $65.00 | N/A | |
| 8/17/2015 | FIX | Reiterated Rating | add | | N/A | |
(Data available from 7/27/2015 forward)
Earnings History for Esperion Therapeutics (NASDAQ:ESPR)Earnings History by Quarter for Esperion Therapeutics (NASDAQ ESPR)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/1/2017 | Q1 2017 | ($1.44) | ($1.80) | | | View | N/A | |
| 2/22/2017 | 12/31/2016 | ($1.24) | ($1.29) | | | View | N/A | |
| 11/3/2016 | Q3 | ($0.82) | ($0.77) | | | View | N/A | |
| 8/4/2016 | Q2 | ($0.78) | ($0.62) | | | View | N/A | |
| 5/4/2016 | Q116 | ($0.74) | ($0.65) | | | View | N/A | |
| 2/25/2016 | Q4 | ($0.61) | ($0.58) | | | View | N/A | |
| 11/5/2015 | Q3 | ($0.60) | ($0.57) | | | View | N/A | |
| 8/6/2015 | Q215 | ($0.58) | ($0.55) | | | View | N/A | |
| 5/7/2015 | Q115 | ($0.54) | ($0.56) | | | View | N/A | |
| 3/5/2015 | Q4 2014 | ($0.54) | ($0.49) | | | View | N/A | |
| 8/12/2014 | Q214 | ($0.55) | ($0.60) | | | View | N/A | |
| 5/12/2014 | Q1 2014 | ($0.62) | ($0.51) | | | View | N/A | |
| 3/5/2014 | | ($0.50) | ($0.63) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Esperion Therapeutics (NASDAQ:ESPR)| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q2 2017 | 1 | ($1.38) | ($1.38) | ($1.38) |
| Q3 2017 | 1 | ($1.40) | ($1.40) | ($1.40) |
| Q4 2017 | 1 | ($1.42) | ($1.42) | ($1.42) |
(Data provided by Zacks Investment Research)
Dividend History for Esperion Therapeutics (NASDAQ:ESPR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Esperion Therapeutics (NASDAQ:ESPR)Insider Ownership Percentage: 32.50%
Institutional Ownership Percentage: 80.50%
Insider Trades by Quarter for Esperion Therapeutics (NASDAQ:ESPR)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 3/22/2017 | Dov A Md Goldstein | Director | Sell | 800,000 | $41.66 | $33,328,000.00 | |
| 3/21/2017 | Gilbert S Omenn | Director | Buy | 1,000 | $42.26 | $42,260.00 | |
| 11/1/2016 | Narendra D Lalwani | COO | Buy | 5,000 | $9.93 | $49,650.00 | |
| 7/6/2016 | Mark E Mcgovern | Director | Buy | 5,000 | $10.00 | $50,000.00 | |
| 5/4/2016 | Timothy M Mayleben | CEO | Buy | 7,000 | $14.85 | $103,950.00 | |
| 3/1/2016 | Gilbert S Omenn | Director | Buy | 5,000 | $15.28 | $76,400.00 | |
| 1/27/2016 | Timothy M Mayleben | CEO | Buy | 3,600 | $15.88 | $57,168.00 | |
| 1/15/2016 | Timothy M Mayleben | CEO | Buy | 7,200 | $14.08 | $101,376.00 | |
| 4/24/2015 | Dov A Md Goldstein | Director | Sell | 217,469 | $108.22 | $23,534,495.18 | |
| 11/18/2014 | Patrick G Enright | Director | Sell | 487,130 | $32.78 | $15,968,121.40 | |
| 10/21/2014 | Parters Vii L P Domain | Major Shareholder | Buy | 500,000 | $20.00 | $10,000,000.00 | |
| 10/7/2014 | Longitude Capital Partners, Ll | Major Shareholder | Sell | 11,927 | $30.04 | $358,287.08 | |
| 7/1/2013 | Brian H Dovey | Major Shareholder | Buy | 285,714 | $14.00 | $3,999,996.00 | |
| 7/1/2013 | Daniel Janney | Director | Buy | 235,714 | $14.00 | $3,299,996.00 | |
| 7/1/2013 | Roger S Newton | Chairman | Buy | 42,346 | $14.00 | $592,844.00 | |
| 7/1/2013 | Timothy M Mayleben | CEO | Buy | 5,000 | $14.00 | $70,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Esperion Therapeutics (NASDAQ:ESPR)
Latest Headlines for Esperion Therapeutics (NASDAQ:ESPR)
| Source: |
|
| Date | Headline |
|---|
 | The CEO Behind Lipitor Is Working on a Promising New Cholesterol Drug - Motley Fool
www.fool.com - July 26 at 6:59 PM |
 | Esperion Therapeutics (ESPR) Reports Initiation of Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor - StreetInsider.com
www.streetinsider.com - July 26 at 6:59 PM |
 | Esperion Announces Initiation of Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor
finance.yahoo.com - July 26 at 6:59 PM |
| 3 Small Biotech Stocks Being Run by Proven Winners
finance.yahoo.com - July 17 at 10:56 AM |
 | Esperion Therapeutics, Inc. (ESPR) to Post Q2 2017 Earnings of ($1.38) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - July 13 at 10:02 AM |
| Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 11 at 5:34 PM |
| Esperion Therapeutics, Inc. (ESPR) Coverage Initiated by Analysts at Jefferies Group LLC
www.americanbankingnews.com - July 10 at 5:26 PM |
| 3 Stocks That Turned $7,000 Into As Much As $37,000 So Far in 2017
finance.yahoo.com - July 8 at 10:33 AM |
 | Esperion Therapeutics: Is Investor Enthusiasm Justified? - Seeking Alpha
seekingalpha.com - July 6 at 1:50 AM |
 | Biotech Movers: Akebia Shares Down After Pricing Stock Offering - TheStreet.com
www.thestreet.com - June 30 at 6:01 AM |
| Today's Research Reports on Stocks to Watch: Heat Biologics Inc. and Esperion Therapeutics
finance.yahoo.com - June 29 at 7:56 PM |
 | Here's Why Shares of Esperion Therapeutics (ESPR) Popped Today - Nasdaq
www.nasdaq.com - June 29 at 4:51 AM |
| Here's Why Shares of Esperion Therapeutics (ESPR) Popped Today
finance.yahoo.com - June 28 at 11:50 PM |
| Esperion Breaks Out On Cholesterol Tie-Up With Dow's Merck
finance.yahoo.com - June 28 at 6:47 PM |
| Esperion's Combo Cholesterol Candidate Enters Phase III
www.nasdaq.com - June 28 at 1:46 PM |
| Esperion's Combo Cholesterol Candidate Enters Phase III
finance.yahoo.com - June 28 at 1:46 PM |
| Esperion Therapeutics (ESPR) Reports FDA Confirmation of Regulatory Pathway to Approval for the Combination of ... - StreetInsider.com
www.streetinsider.com - June 26 at 11:04 PM |
| Esperion Therapeutics, Inc. (ESPR) Rating Reiterated by Stifel Nicolaus
www.americanbankingnews.com - June 26 at 10:44 PM |
| Esperion Therapeutics (ESPR) Reports FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid & Ezetimibe
www.streetinsider.com - June 26 at 6:02 PM |
| Esperion Announces FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid and Ezetimibe
finance.yahoo.com - June 26 at 6:02 PM |
| Esperion Therapeutics, Inc. (ESPR) Upgraded to Buy at BidaskClub
www.americanbankingnews.com - June 25 at 3:04 PM |
| Esperion Therapeutics, Inc. (ESPR) Given Buy Rating at Citigroup Inc.
www.americanbankingnews.com - June 24 at 11:56 AM |
| Esperion Therapeutics, Inc. (ESPR) Now Covered by Analysts at Deutsche Bank AG
www.americanbankingnews.com - June 23 at 12:12 PM |
| Comparing Spectrum Pharmaceuticals (SPPI) & Esperion Therapeutics (ESPR)
www.americanbankingnews.com - June 22 at 4:44 PM |
| Biotechs Surge As Generalists Return Amid Subsiding Trump Woes
finance.yahoo.com - June 21 at 6:36 PM |
| Esperion Therapeutics, Inc. (ESPR) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - June 16 at 3:04 PM |
 | Esperion to Present at the JMP Securities 2017 Life Sciences Conference - GlobeNewswire (press release)
globenewswire.com - June 14 at 6:13 PM |
| Esperion to Present at the JMP Securities 2017 Life Sciences Conference
finance.yahoo.com - June 14 at 6:13 PM |
| Apple Could Explode Higher to $200 a Share If This Chart Pattern Is Correct
finance.yahoo.com - June 9 at 5:30 PM |
 | Recent ALXN News
www.bloomberg.com - June 8 at 11:06 PM |
| Esperion Therapeutics Inc (ESPR) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - June 4 at 6:46 PM |
| Commit To Purchase Esperion Therapeutics At $27, Earn 21.2% Annualized Using Options - Nasdaq
www.nasdaq.com - June 1 at 5:47 PM |
| Esperion Therapeutics Inc (ESPR) Expected to Post Earnings of -$1.73 Per Share
www.americanbankingnews.com - May 30 at 7:38 AM |
| Esperion Therapeutics Inc (ESPR) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 22 at 2:17 PM |
| Esperion Provides Update on Common Stock Trading Activity
finance.yahoo.com - May 22 at 11:42 AM |
| Esperion Therapeutics: Up, Up, And Away? - Seeking Alpha
seekingalpha.com - May 19 at 9:51 PM |
| Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference
finance.yahoo.com - May 19 at 4:49 PM |
| Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - May 19 at 5:19 AM |
| Esperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2017 Healthcare Conference
finance.yahoo.com - May 12 at 5:34 PM |
| Esperion Therapeutics Inc (ESPR) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - May 9 at 7:30 PM |
| Today's Research Report on Biotech Stocks to Watch: Immunomedics and Esperion Therapeutics
finance.yahoo.com - May 8 at 9:08 AM |
| Why Esperion Therapeutics Shares Were Flat In April
finance.yahoo.com - May 6 at 10:37 AM |
| Esperion Therapeutics reports 1Q loss
finance.yahoo.com - May 5 at 5:16 PM |
| Esperion Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 4 at 5:11 PM |
| Zacks: Analysts Anticipate Esperion Therapeutics Inc (ESPR) Will Announce Earnings of -$1.48 Per Share
www.americanbankingnews.com - May 4 at 1:26 PM |
| Esperion Therapeutics (ESPR) Receiving Somewhat Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - May 2 at 9:52 AM |
| Esperion Therapeutics Inc (ESPR) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 1 at 9:30 PM |
| Somewhat Favorable Press Coverage Extremely Likely to Impact Esperion Therapeutics (ESPR) Stock Price
www.americanbankingnews.com - April 29 at 12:53 PM |
| Esperion Therapeutics Inc (ESPR) to Release Earnings on Monday
www.americanbankingnews.com - April 29 at 7:09 AM |
| Esperion Therapeutics (ESPR) Receives Daily Coverage Optimism Score of 0.20
www.americanbankingnews.com - April 27 at 1:11 AM |
Esperion Therapeutics (ESPR) Chart for Thursday, July, 27, 2017
